Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tacrolimus

FDA-approved product (capsule, oral), marketed as Astagraf Xl, Envarsus Xr, Prograf and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tacrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Delayed Graft Function
  • Eczematoid dermatitis
  • Immune system disease
  • Kidney transplant
  • Liver transplant

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Calcineurin inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tacrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tacrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis

    NCT01207297 · start 2003-03

    Registered record
    Registry ID
    NCT01207297
    Conditions
    SLE; Lupus Nephritis; Renal Insufficiency; End-stage Renal Disease
    Interventions
    Tacrolimus; cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-03
    Completion
    2010-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSLE; Lupus Nephritis; Renal Insufficiency; End-stage Renal Disease
    InterventionTacrolimus; cyclophosphamide
    PhasePhase 1
    Registry statusCompleted

  • Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

    NCT00499889 · start 2003-02

    Registered record
    Registry ID
    NCT00499889
    Conditions
    Leukemia
    Interventions
    Imatinib Mesylate; Fludarabine (Fludara); Busulfan; Antithymocyte Globulin (ATG); Tacrolimus; Methotrexate; Donor lymphocyte infusion (DLI); Stem Cell Transplant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-02
    Completion
    2009-11
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionImatinib Mesylate; Fludarabine (Fludara); Busulfan; Antithymocyte Globulin (ATG) +4 more
    PhasePhase 2
    Registry statusTerminated

  • Pre Transplant Rapamycin Treatment in Islet Transplantation Alone

    NCT01060605 · start 2001-10

    Registered record
    Registry ID
    NCT01060605
    Conditions
    Diabetes Mellitus, Type 1
    Interventions
    rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10
    Completion
    2009-09
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1
    Interventionrapamycin
    PhasePhase 3
    Registry statusCompleted

  • Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

    NCT00048399 · start 2000-12

    Registered record
    Registry ID
    NCT00048399
    Conditions
    Graft Failure
    Interventions
    Fludarabine; CAMPATH 1H; FK506; Stem Cell Transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2000-12
    Completion
    2003-10-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft Failure
    InterventionFludarabine; CAMPATH 1H; FK506; Stem Cell Transplantation
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)

    NCT00290069

    Registered record
    Registry ID
    NCT00290069
    Conditions
    Kidney Diseases; Graft Rejection
    Interventions
    Tacrolimus; Rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Graft Rejection
    InterventionTacrolimus; Rapamycin
    PhasePhase 4
    Registry statusUnknown